Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Yasutaka Kawai"'
Autor:
Kana Hashimoto, MD, Daisuke Morinaga, MD, Hajime Asahina, MD, PhD, Mina Ishidoya, MD, Hajime Kikuchi, MD, PhD, Hiroshi Yokouchi, MD, PhD, Toshiyuki Harada, MD, PhD, Osamu Honjo, MD, Ryota Shigaki, MD, Taichi Takashina, MD, PhD, Yuka Fujita, MD, PhD, Mamoru Takahashi, MD, PhD, Yasutaka Kawai, MD, Ryotaro Kida, MD, Kenichiro Ito, MD, Noriaki Sukoh, MD, PhD, Ayumu Takahashi, MD, PhD, Fumihiro Hommura, MD, PhD, Yoshihito Ohhara, MD, PhD, Megumi Furuta, MD, PhD, Satoshi Konno, MD, PhD, Yukio Hosomi, MD, PhD, Satoshi Oizumi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 11, Pp 100715- (2024)
Introduction: Oligometastasis and oligoprogression (OP) has not been adequately defined in extensive-stage SCLC (ES-SCLC) and may be a good indication for adding local treatment. Therefore, this multicenter study aimed to investigate the prognostic i
Externí odkaz:
https://doaj.org/article/6a9e9af6ebb84315b50bcf56a349d75d
Autor:
Daisuke Morinaga, Hajime Asahina, Shotaro Ito, Osamu Honjo, Hisashi Tanaka, Ryoichi Honda, Hiroshi Yokouchi, Keiichi Nakamura, Kei Takamura, Fumihiro Hommura, Yasutaka Kawai, Kenichiro Ito, Noriaki Sukoh, Keiki Yokoo, Ryo Morita, Toshiyuki Harada, Taichi Takashina, Tomohiro Goda, Hirotoshi Dosaka‐Akita, Hiroshi Isobe, the Hokkaido Lung Cancer Clinical Study Group Trial
Publikováno v:
Cancer Medicine, Vol 12, Iss 10, Pp 11525-11541 (2023)
Abstract Purpose Immune‐checkpoint inhibitors (ICIs) are effective against advanced non‐small cell lung cancer (NSCLC). However, whether the efficacy and safety of ICI treatment in elderly patients are similar to those in younger patients is uncl
Externí odkaz:
https://doaj.org/article/e841a5a350844541b0287c7aee9ab30b
Autor:
Hisashi Tanaka, Yukihiro Hasegawa, Yuka Fujita, Atsushi Nakamura, Eiki Kikuchi, Yasutaka Kawai, Toshiyuki Harada, Naomi Watanabe, Hiroshi Yokouchi, Kazuhiro Usui, Ryota Saito, Hiroshi Watanabe, Tomomi Masuda, Tatsuro Fukuhara, Keita Kudo, Ryoichi Honda, Satoshi Oizimi, Makoto Maemondo, Akira Inoue, Naoto Morikawa
Publikováno v:
Thoracic Cancer, Vol 12, Iss 14, Pp 2113-2121 (2021)
Abstract Background A cisplatin plus irinotecan (CPT‐11) regimen is used for patients with extensive disease small cell lung cancer (ED‐SCLC). Amrubicin (AMR) is primarily used for relapsed SCLC. The HOT1401/NJLCG1401 trial, an open‐label rando
Externí odkaz:
https://doaj.org/article/c0e9bc75e14647f5afcebfe007cf88f5
Autor:
Hideaki Ono, Yasutaka Kawai, Seisuke Ata, Hiroyuki Minamikawa, Kazuma Kurihara, Shinji Tanaka, Masaru Yoshida
Publikováno v:
Macromolecular Rapid Communications.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c83eaa0de34cefed7d98914267a02a3
https://doi.org/10.1002/marc.202300155
https://doi.org/10.1002/marc.202300155
Publikováno v:
Haigan. 61:412-416
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::618c0c7d5f6dfe6cf897e39eb2c74af5
https://doi.org/10.2482/haigan.61.412
https://doi.org/10.2482/haigan.61.412
Autor:
Kei Takakura, Haruno Murayama, Makoto Tokunaga, Otsuki Shujiro, Hiroshi Sakata, Moemi Kimura, Hironobu Matsueda, Yasutaka Kawai, Eiji Yamamoto
Publikováno v:
ChemCatChem. 13:4694-4699
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57864be06064d74303cbbf118d8d73a1
https://doi.org/10.1002/cctc.202101092
https://doi.org/10.1002/cctc.202101092
Publikováno v:
Haigan. 61:310-314
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb67090105aab726ce0e7e283d21e84e
https://doi.org/10.2482/haigan.61.310
https://doi.org/10.2482/haigan.61.310
Autor:
Keita Kudo, Tomomi Masuda, Toshiyuki Harada, Kazuhiro Usui, Eiki Kikuchi, Yukihiro Hasegawa, Akira Inoue, Satoshi Oizimi, Atsushi Nakamura, Makoto Maemondo, Tatsuro Fukuhara, Yuka Fujita, Ryoichi Honda, Hiroshi Yokouchi, Hiroshi Watanabe, Naomi Watanabe, Hisashi Tanaka, Ryota Saito, Naoto Morikawa, Yasutaka Kawai
Publikováno v:
Thoracic Cancer, Vol 12, Iss 14, Pp 2113-2121 (2021)
Thoracic Cancer
Thoracic Cancer
Background A cisplatin plus irinotecan (CPT‐11) regimen is used for patients with extensive disease small cell lung cancer (ED‐SCLC). Amrubicin (AMR) is primarily used for relapsed SCLC. The HOT1401/NJLCG1401 trial, an open‐label randomized pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99792828c290e8790a7eff3d24e96d99
https://doaj.org/article/c0e9bc75e14647f5afcebfe007cf88f5
https://doaj.org/article/c0e9bc75e14647f5afcebfe007cf88f5
Publikováno v:
Molecular and Clinical Oncology
Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare type of lung cancer, accounting for 3% of all lung cancers. The prognosis is poor and the standard therapy has not been well established. Herein, we report a case of advanced LCNEC of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea5ebe2a7ef7a861072b27b6f1ee478a
http://europepmc.org/articles/PMC7265227
http://europepmc.org/articles/PMC7265227
Autor:
Yasutaka Kawai, Kazuki Haruguchi, Keisei Sumikawa, Mai Kawada, Eiji Yamamoto, Haruno Murayama, Makoto Tokunaga
Publikováno v:
Applied Catalysis A: General. 643:118781
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9dc3623a9ce1ef0188efd8ff8b551615
https://doi.org/10.1016/j.apcata.2022.118781
https://doi.org/10.1016/j.apcata.2022.118781